Efficacy and Safety of Lenacapavir for HIV Pre-Exposure Prophylaxis (Prep): A Systematic Review

Putu Ngurah Pradnya Wibawa; Ni Putu Lia Juliantini; Ni Luh Putu Serly  Ekayanti

doi:10.59141/jiss.v7i5.2316

Authors

Putu Ngurah Pradnya Wibawa UPTD Dawan II Community Health Center, Indonesia
Ni Putu Lia Juliantini UPTD Dawan II Community Health Center, Indonesia
Ni Luh Putu Serly Ekayanti UPTD Dawan II Community Health Center, Indonesia

DOI:

https://doi.org/10.59141/jiss.v7i5.2316

Keywords:

HIV Prevention, Lenacapavir, Pre-Exposure Prophylaxis (PrEP), Efficacy, Safety

Abstract

Lenacapavir, an antiretroviral agent, is a candidate for HIV prophylaxis, distinguished by its long-acting formulation, which facilitates biannual administration for preventive care. The objective of this investigation is to assess the efficacy and safety profile of Lenacapavir, drawing upon the findings of extant research. This scoping review analyzed articles published between march 2016 and march 2026 from PubMed, ScienceDirect, and OpenAlex. The inclusion criteria comprised English-language cohort studies, case-control studies, and cross-sectional studies examining the association between NAFLD and the risk of CKD. Fifteen articles were selected following a rigorous screening process. Lenacapavir is a highly effective HIV preventive drug that can reduce the risk of HIV transmission among various populations, including pregnant women, homosexual and heterosexual individuals, and others. The reported side effects are generally mild and not severe. Lenacapavir signifies a significant advancement in the realm of HIV prevention, especially for individuals at elevated risk who encounter challenges with consistent daily medication adherence. The effective global deployment of this intervention hinges on several critical factors: guaranteeing equitable accessibility, ensuring affordability within low- and middle-income nations, and upholding rigorous HIV testing protocols to mitigate the potential for viral resistance.

References

Baeten, J. M. (2025). Lenacapavir for HIV prevention: A commitment to equitable access and partnership by Gilead Sciences. Clinical Infectious Diseases, 81(3), 555–560.

Cantos, V. D., Ramírez, B. C., Kelley, C. F., del Rio, C., & Grinsztejn, B. (2025). Lenacapavir: A potential game changer for HIV prevention in the Americas, if the game is played equitably. The Lancet Regional Health – Americas, 47, 101146.

Centers for Disease Control and Prevention (CDC). (2025). Clinical recommendation for the use of injectable lenacapavir as HIV PrEP.

Eron, J. J., Little, S. J., Crofoot, G., Cook, P., Ruane, P. J., Jayaweera, D., VanderVeen, L. A., DeJesus, E., Zheng, Y., & Mills, A. (2024). Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: A phase 1b, randomised, proof-of-concept study. The Lancet HIV, 11(3), e146–e155.

Fonner, V., et al. (2025). WHO guidelines on lenacapavir for HIV prevention.

Goswami, S., Veeramachaneni, S., & Masurkar, P. P. (2025). Lenacapavir for HIV PrEP: Narrative review.

Haberer, J. E., Mujugira, A., & Mayer, K. H. (2023). The future of HIV pre-exposure prophylaxis adherence: Reducing barriers and increasing opportunities. The Lancet HIV, 10(6), e404–e411.

Hempel, A., Biondi, M. J., Baril, J.-G., & Tan, D. H. S. (2022). Pre-exposure prophylaxis for HIV: Effective and underused. CMAJ, 194(34), E1164–E1170.

Kristyanto, H., González-Tomé, M. I., Vlcek, V., Josephson, F., Vrijlandt, P., & Perombelon, N. (2026). Global regulatory collaboration for the assessment of lenacapavir as a long-acting pre-exposure prophylaxis against HIV infection. Frontiers in Public Health, 14, 1760130.

Mukuhlani, B. T., & Assaré, R. K. (2026). Efficacy and safety of long-acting lenacapavir for HIV treatment and prevention: A systematic review of randomized trials. International Journal of Infectious Diseases, 108580.

National Institutes of Health (NIH). (2024). Lenacapavir for HIV prevention clinical trials.

Nozza, S., & Castagna, A. (2024). Twice-yearly lenacapavir: A milestone for HIV prevention in young African women. Med, 5(10), 1200–1202.

O Murchu, E., Marshall, L., Teljeur, C., Harrington, P., Hayes, C., Moran, P., & Ryan, M. (2022). Oral pre-exposure prophylaxis (PrEP) to prevent HIV: A systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open, 12(5), e048478.

Ogbuagu, O., Segal-Maurer, S., Ratanasuwan, W., Avihingsanon, A., Brinson, C., Workowski, K., Antinori, A., Yazdanpanah, Y., Trottier, B., & Wang, H. (2023). Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: Week 52 results of a phase 2/3 trial. The Lancet HIV, 10(8), e497–e505.

Patel, R. R., Hoover, K. W., Lale, A., Cabrales, J., Byrd, K. M., & Kourtis, A. P. (2025). Clinical recommendation for the use of injectable lenacapavir as HIV preexposure prophylaxis—United States, 2025. MMWR Morbidity and Mortality Weekly Report, 74(35), 542–550.

Sanaullah, K., Hasan, A. H., & Abid, M. A. (2025). FDA-approved HIV-1 capsid inhibition with lenacapavir: A paradigm shift in pre-exposure prophylaxis. Cureus, 17(9), e92043.

Segal-Maurer, S., DeJesus, E., Stellbrink, H.-J., Castagna, A., Richmond, G. J., Sinclair, G. I., Siripassorn, K., Ruane, P. J., Berhe, M., & Wang, H. (2022). Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. New England Journal of Medicine, 386(19), 1793–1803.

Stewart, J., & Baeten, J. M. (2022). HIV pre-exposure prophylaxis and sexually transmitted infections: Intersection and opportunity. Nature Reviews Urology, 19(1), 7–15.

World Health Organization (WHO). (2024). Long-acting injectable lenacapavir for HIV prevention.

Xu, S., & Zhan, P. (2024). Twice-yearly lenacapavir demonstrated exceptional efficacy for HIV prevention. The Innovation, 5(5), 100683.